Decreased blood riboflavin levels are correlated with defective expression of RFT2 gene in gastric cancer

Table 1 Statistical analysis of riboflavin transporter 2 expression and clinicopathologic factors in gastric cancer n (%)

Characteristics	n	RFT2 expression				Z	P value
		−	+	++	+++
Normal mucous epithelia	60	6 (10.0)	10 (16.7)	16 (26.7)	28 (46.7)	-7.937	< 0.001
Gastric cancer	60	45 (75.0)	10 (16.7)	5 (8.3)	0
Gender
Male	39	31 (79.5)	6 (15.4)	3 (7.7)	0	-0.621	0.534
Female	21	14 (66.7)	4 (19.0)	2 (9.5)	0
Ethnic groups
Han	32	21 (55.0)	8 (25.0)	3 (20.0)	0	-1.943	0.052
Uyghur	28	24 (81.82)	2 (13.6)	2 (4.5)	0
Tumor location
Cardia of stomach	10	2 (20.0)	4 (40.0)	4 (40.0)	0	-3.127	0.209
Body of stomach	11	8 (72.1)	2 (18.2)	1 (8.7)	0
Antrum of stomach	39	35 (89.7)	4 (10.3)	0	0
Differentiation
Moderate/well	19	10 (52.6)	5 (26.3)	4 (21.1)	0	-2.834	0.005
Poor	41	35 (85.4)	5 (12.2)	1 (2.3)	0
L/N metastasis
Negative	10	9 (90.0)	1 (10.0)	0	0	-1.245	0.28
Positive	50	36 (72.0)	9 (18.0)	5 (10.0)
Stage
II and IIIa	41	27 (65.9)	9 (22.0)	5 (12.1)	0	-2.414	0.019
IIIb and IV	19	18 (94.7)	1 (5.3)	0	0

Table 2 Statistical analysis of riboflavin transporter 2 expression and blood riboflavin levels in gastric cancer (mean ± SD)

RFT2 protein expression	Riboflavin level	χ2	P value
−	0.7012 ± 0.68 778	-2.619	0.019
+	1.6425 ± 1.01 783
++	2.9691 ± 1.30 345